FDA Grants Fast Track Designation to Nouscom's NOUS-209 for Lynch Syndrome Cancer Prevention
核心洞察
The U.S. FDA has granted Fast Track Designation to NOUS-209, an investigational immunotherapy designed to prevent Lynch Syndrome (搜索)-associated cancers in carriers with confirmed mismatch repair (搜索) mutations.
Phase 1b/2 data published in Nature Medicine demonstrated that NOUS-209 was safe and induced broad, potent T cell responses, with no new advanced adenomas detected one year post-treatment.
The designation enables more frequent FDA interactions and eligibility for accelerated review processes as Nouscom (搜索) advances toward a registration-enabling Phase 2/3 trial.
Nouscom (搜索) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to NOUS-209 for the prevention of Lynch Syndrome (搜索)-associated cancers in carriers with genetically confirmed mismatch repair (搜索) mutations. The designation recognizes the therapy's potential to address a serious condition with significant unmet medical need and expedites development through more frequent FDA interactions.
Clinical Evidence Supporting the Designation
The Fast Track Designation is supported by Phase 1b/2 data in Lynch Syndrome (搜索) carriers published in Nature Medicine, demonstrating that NOUS-209 monotherapy was safe and induced broad, potent, functional and durable T cell responses, boosted by annual retreatment. Notably, no new advanced adenomas were detected one year post-treatment, providing first clinical evidence of cancer interception in Lynch Syndrome carriers.
"Lynch Syndrome (搜索) carriers face up to 80% lifetime risk of developing cancer. Yet their only options today are intensive surveillance or prophylactic organ removal surgery," said Marina Udier, Ph.D., Chief Executive Officer of Nouscom (搜索). "Fast Track Designation from the FDA validates the urgency of the need and the strength of our NOUS-209 program."
Mechanism and Development Strategy
NOUS-209 is an investigational off-the-shelf cancer immunotherapy that targets tumors with mismatch repair (搜索) deficiency and microsatellite instability. The therapy is comprised of two proprietary viral vectors able to deliver 209 shared frameshift peptide neoantigens (搜索) and train the immune system to recognize and attack cancerous and precancerous cells before tumors can develop.
The designation enables eligibility for Accelerated Approval, Rolling Review of a Biologics License Application, and Priority Review at BLA submission. "Fast Track Designation will accelerate our dialogue with the FDA as we prepare for our registration-enabling study," said Sven Gogov, M.D., Chief Medical Officer of Nouscom (搜索).
Lynch Syndrome Disease Burden
Lynch Syndrome (搜索) is a common inherited condition that significantly increases cancer risk over a person's lifetime, particularly colorectal cancer (搜索) (up to 50% risk, compared to 2% for the general population), endometrial cancer (搜索) (up to 50% risk, compared to 1-2% for the general population) and urothelial cancer (搜索) (up to 25% risk, compared to 1-2% for the general population). The syndrome also elevates the risk of developing gastric, ovarian, prostate and pancreatic cancers.
Currently, managing Lynch Syndrome (搜索) is limited to frequent screenings such as colonoscopy to catch cancer early, but this approach is not shown to reduce cancer incidence, and elective surgery, which is invasive, expensive, and negatively impacts quality of life.
Broader Clinical Development
NOUS-209 is also being studied in Phase 2 studies in combination with pembrolizumab in advanced mismatch repair (搜索) deficient and/or microsatellite instability-high metastatic colorectal cancer (搜索) patients refractory to anti-PD-1 (搜索) therapy, and in first line treatment of advanced dMMR and/or MSI-H metastatic colorectal cancer. Data from the successfully completed Phase 1b trial were published in Science Translational Medicine.
The company plans to advance NOUS-209 into a registration-enabling Phase 2/3 trial in cancer interception, building on the momentum from the Fast Track Designation and prior regulatory alignment with both FDA and EMA on the registrational path.